Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Latest From Jung Won Shin
SillaJen selects another Korean firm as its new owner as trading in its stock continues to be suspended following the probe into its former CEO. But it remains to be seen whether the acquisition can catalyze a business breakthrough and speed up clinical development for the oncolytic immunotherapeutic firm.
A recent industry forum in South Korea heard expert views on the issues and strategies required to take the country over the finish line in the development of home-grown blockbuster, and to progress the big licensing-out deals reached over the past few years.
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Korea's AriBio is poised to file for US Phase III trial approval this year for its novel Alzheimer's candidate and lead asset AR1001, which showed an improvement in cognitive function from baseline at Phase II. But will the benefits over existing therapies be enough to carve a position in the challenging field?
South Korean conglomerate SK Group continues its cross-border acquisitions of contract manufacturers, this time of French biologics specialist Yposkesi, marking a new push into the gene and cell therapy sector as it looks to become a global leader in the production of both innovative chemical drugs and biologics.
Since being established in 2012, Samsung Bioepis has grown into a global biosimilars leader with one of the most robust portfolios of products and pipelines in the sector. Its executive vice-president talks about what is behind this rapid growth and the strategy the Samsung Group affiliate is pursuing to cope with the COVID-19 pandemic and become a fully integrated operation in the longer term.